|
07/11/2024
|
07:00
|
Conversion of Convertible Loan Notes
|
RNS
|
|
27/09/2024
|
07:00
|
Interim Results to 30 June 2024
|
RNS
|
|
23/09/2024
|
07:00
|
Grant of Japan MK Cell Patent
|
RNS
|
|
19/09/2024
|
07:00
|
STAT-6 siRNA Demonstrates Efficacy in Immunology
|
RNS
|
|
02/09/2024
|
07:00
|
Grant of MK Cell Patent & Licencing Update
|
RNS
|
|
27/06/2024
|
12:46
|
Results of AGM
|
RNS
|
|
20/06/2024
|
07:00
|
Appointment of Broker
|
RNS
|
|
04/06/2024
|
07:00
|
Notice of Annual General Meeting
|
RNS
|
|
23/05/2024
|
07:05
|
Issue of Convertible Loan Notes & Board Changes
|
RNS
|
|
23/05/2024
|
07:00
|
Midkine Antibody Licencing Deal
|
RNS
|
|
26/04/2024
|
07:00
|
Annual Report & Financial Statements - 31 Dec 2023
|
RNS
|
|
05/04/2024
|
07:00
|
Response to Share Price Movement
|
RNS
|
|
11/03/2024
|
07:00
|
Positive Results: Midkine mRNA and STAT-6 siRNA
|
RNS
|
|
06/02/2024
|
07:00
|
Operations Update
|
RNS
|
|
24/11/2023
|
07:00
|
Change of Auditor
|
RNS
|
|
06/11/2023
|
07:00
|
Significant Mesodermal Killer Cell Milestone
|
RNS
|
|
27/09/2023
|
07:00
|
Interim Results to 30 June 2023
|
RNS
|
|
14/08/2023
|
07:00
|
Expansion of Patent Portfolio
|
RNS
|
|
07/08/2023
|
07:00
|
Development of New Novel siRNA Therapeutics
|
RNS
|
|
02/08/2023
|
07:00
|
Director/PDMR Shareholding
|
RNS
|
|
12/07/2023
|
10:27
|
Director/PDMR Shareholding
|
RNS
|
|
29/06/2023
|
10:05
|
Results of AGM
|
RNS
|
|
29/06/2023
|
07:00
|
AGM Statement
|
RNS
|
|
26/06/2023
|
14:41
|
Director/PDMR Shareholding
|
RNS
|
|
26/06/2023
|
10:36
|
Director/PDMR Shareholding
|
RNS
|
|
26/06/2023
|
10:00
|
Director/PDMR Shareholding
|
RNS
|
|
22/06/2023
|
07:00
|
RNA Medicine Shows In Vitro Anti-Cancer Efficacy
|
RNS
|
|
19/06/2023
|
07:00
|
Antibody Program Results & Orphan Drug Indication
|
RNS
|
|
13/06/2023
|
07:00
|
Anti-Cancer MDK mRNA - Positive in vitro Results
|
RNS
|
|
07/06/2023
|
10:11
|
Restoration of Trading
|
RNS
|
|
06/06/2023
|
07:00
|
Notice of Annual General Meeting
|
RNS
|
|
05/06/2023
|
07:00
|
Annual Report & Financial Statements - 31 Dec 2022
|
RNS
|
|
02/05/2023
|
07:56
|
Suspension of Trading Pending 2022 Annual Report
|
RNS
|
|
02/05/2023
|
07:30
|
Suspension - Roquefort Therapeutics plc
|
RNS
|
|
13/03/2023
|
07:30
|
Confirmation of No Exposure to Silicon Valley Bank
|
RNS
|
|
08/03/2023
|
07:00
|
Creation of New Novel Family of mRNA Therapeutics
|
RNS
|
|
06/03/2023
|
07:00
|
Formation of Scientific Advisory Board
|
RNS
|
|
20/02/2023
|
07:00
|
Randox Licence and Royalty Agreement
|
RNS
|
|
24/01/2023
|
07:00
|
MDK Oncology Antibodies Demonstrate In-Vivo Safety
|
RNS
|
|
18/01/2023
|
08:36
|
Holding(s) in Company
|
RNS
|
|
16/01/2023
|
07:00
|
Appointment of Auditor
|
RNS
|
|
09/01/2023
|
07:00
|
Operations Update
|
RNS
|
|
01/12/2022
|
14:00
|
Resignation of Auditor
|
RNS
|
|
28/09/2022
|
07:00
|
Director/PDMR Shareholding
|
RNS
|
|
26/09/2022
|
14:30
|
Director/PDMR Shareholding
|
RNS
|
|
23/09/2022
|
07:00
|
Interim Results to 30 June 2022
|
RNS
|
|
16/09/2022
|
08:00
|
Investor Presentation
|
RNS
|
|
16/09/2022
|
07:01
|
Board and Management Appointments
|
RNS
|
|
16/09/2022
|
07:00
|
Acquisition Completion, Admission & Voting Rights
|
RNS
|
|
15/09/2022
|
12:26
|
Notice of Admission
|
RNS
|